Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 2
2016 3
2017 2
2018 2
2019 4
2020 8
2021 16
2022 14
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, Noda Y, Nakano M, Suga H, Kuromatsu R, Torimura T, Koga H, Kawaguchi T. Shimose S, et al. Among authors: shirono t. Int J Mol Sci. 2023 Sep 5;24(18):13715. doi: 10.3390/ijms241813715. Int J Mol Sci. 2023. PMID: 37762018 Free PMC article.
Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial.
Goto Y, Niizeki T, Fukutomi S, Shirono T, Shimose S, Iwamoto H, Kojima S, Kanno H, Uchino Y, Sasaki S, Shirahama N, Muroya D, Nomura Y, Akashi M, Nakayama G, Hirakawa Y, Sato T, Yoshitomi M, Sakai H, Hisaka T, Kakuma T, Koga H, Torimura T, Akagi Y, Okuda K. Goto Y, et al. Among authors: shirono t. Kurume Med J. 2023 Sep 25;68(3.4):239-245. doi: 10.2739/kurumemedj.MS6834010. Epub 2023 Jul 28. Kurume Med J. 2023. PMID: 37518005 Free article. Clinical Trial.
The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwara M, Itano S, Yano Y, Matsugaki S, Moriyama E, Noda Y, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: shirono t. Cancer Med. 2023 Jun;12(11):12325-12335. doi: 10.1002/cam4.5931. Epub 2023 Apr 16. Cancer Med. 2023. PMID: 37062077 Free PMC article.
[A case of difficult treatment of infected pseudoaneurysm of the femoral artery during hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Suzuki H, Shirono T, Niizeki T, Iwamoto H, Shimose S, Noda Y, Nakao K, Yamaguchi S, Miyazaki K, Kawaguchi T. Suzuki H, et al. Among authors: shirono t. Nihon Shokakibyo Gakkai Zasshi. 2023;120(3):263-268. doi: 10.11405/nisshoshi.120.263. Nihon Shokakibyo Gakkai Zasshi. 2023. PMID: 36908145 Japanese.
Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
Tsumura S, Shimose S, Niizeki T, Kuboyama E, Iwamoto H, Tanaka M, Moriyama E, Shirono T, Takaki K, Noda Y, Nakano M, Inoue M, Tsustumi K, Kuromatsu R, Koga H, Higuchi K, Kawaguchi T. Tsumura S, et al. Among authors: shirono t. J Gastroenterol Hepatol. 2023 Jul;38(7):1140-1147. doi: 10.1111/jgh.16168. Epub 2023 Mar 16. J Gastroenterol Hepatol. 2023. PMID: 36880677
Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, Koga H, Torimura T. Suzuki H, et al. Among authors: shirono t. Cancer Commun (Lond). 2023 Apr;43(4):415-434. doi: 10.1002/cac2.12411. Epub 2023 Feb 24. Cancer Commun (Lond). 2023. PMID: 36825684 Free PMC article.
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: shirono t. Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16. Hepatol Res. 2023. PMID: 36316794
The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function.
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, Koga H, Torimura T, Kawaguchi T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: shirono t. Cancers (Basel). 2022 Oct 5;14(19):4873. doi: 10.3390/cancers14194873. Cancers (Basel). 2022. PMID: 36230795 Free PMC article.
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Shimose S, et al. Among authors: shirono t. Sci Rep. 2022 Oct 11;12(1):17018. doi: 10.1038/s41598-022-21528-2. Sci Rep. 2022. PMID: 36220865 Free PMC article.
51 results